Home
Live Updates
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022 : comparemela.com
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022
SHANGHAI, June 6, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell the...
Related Keywords
China ,
Shanghai ,
United States ,
Canada ,
Chinese ,
America ,
American ,
Raffaele Baffa ,
Zonghai Li ,
American Society Of Clinical Oncology ,
Carsgen Therapeutics Holdings ,
Prnewswire Carsgen Therapeutics Holdings Limited Stock Code ,
Health Canada ,
Eastern Cooperative Oncology Group ,
Therapeutics Holdings Limited ,
Stock Code ,
Clinical Oncology ,
Annual Meeting ,
Multicenter Phase ,
Chimeric Antigen Receptort Cell Therapy ,
Advanced Gastric ,
Preliminary Efficacy Results ,
Gastroesophageal Junction Adenocarcinoma ,
Chief Medical Officer ,
Chief Executive Officer ,
Chief Scientific Officer ,
Nature Medicine ,
North America ,
Orphan Drug ,
Orphan Medicinal Product ,
Regenerative Medicine Advanced Therapy ,
Therapeutics Holdings ,
comparemela.com © 2020. All Rights Reserved.